A RANDOMIZED CONTROLLED TRIAL OF DAPAGLIFLOZIN PLUS ONCE-WEEKLY EXENATIDE VERSUS PLACEBO IN INDIVIDUALS WITH OBESITY AND WITHOUT DIABETES: METABOLIC EFFECTS AND MARKERS ASSOCIATED WITH BODYWEIGHT LOSS
- Lun 4 de Jun 2018
- Sochob
- Tratamiento de la Obesidad